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G&H Do biomarkers currently have a role in hepatocellular carcinoma? 
 
PJ The role of biomarkers in hepatocellular carcinoma (HCC) is controversial. [For 
example, the best-known biomarker in HCC?] [OK]is α-fetoprotein (AFP), which has 
been around for more than 50 years. Many hepatologists use AFP as a diagnostic aid, but 
there are probably an equal number who do not think that the biomarker is any help 
because it is, reputablyreputably, relatively nonspecific. Thus, there are 2 schools of 
thought: one that believes that there is a role for biomarkers in HCC and one that does 
not. 
 
G&H How and why were the BALAD-2 and GALAD biomarker models developed?  
 
PJ Doctors in Japan, [which has a high incidence and prevalence of HCC?], have 
used the biomarkers AFP, des-γ-carboxyprothrombin (DCP), and AFP-L3 for many years 
for the diagnosis of HCC as well as for undertaking surveillance of patients who are at 
high risk for the disease. However, whilst there was still a need for more sensitive and 
specific biomarkers for HCC an alternative approach is to combine existing ones.. [ok to 
add previous sentence?] Thus, the markers were combined BALAD (bilirubin, albumin, 
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 AFP-L3, AFP, and DCP) and GALAD (gender, age, AFP-L3, AFP, and DCP) biomarker 
models were developed [in an attempt to improve the prognostication and diagnosis, 
respectively, of HCC?]. The prognostic BALAD model was developed by Dr Hidenori 
Toyoda and colleagues in 2005. [Why were bilirubin, albumin, AFP-L3, AFP, and 
DCP chosen to be in the model and not other components?] 
 
 
 
Subsequently, my colleagues and I in Birminghamwe, UK [who—“colleagues from 
several European centers and I”?] undertook a close collaboration with [Toyoda and 
colleagues?][OK] to combine their original data with some data of our own and perform 
a rigorous statistical analysis to develop BALAD-2. This biomarker model is very similar 
to the original BALAD model; it just involves a more [complex?] statistical analysis and 
provides a slightly better performance.   
[We can readily give the formula but I am not sure if this would be very informative 
to your reader.  A diagram showing its output might be more relevant][Why was 
BALAD-2 developed? Could you give more specific information on how the analysis 
differs? Is it possible to give the formula?] 
 
 
The diagnostic GALAD model uses the same 3 biomarkers of the BALAD model but 
also considers gender and age. [My colleagues and I?][OK] used data [on AFP, AFP-
L3, and DCP?][OK] from [Toyoda and colleagues?][OK] to build a rigorously 
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 validated statistical model in close collaboration with the Japanese researchers. The 
published formula is 10.08 + 0.09  age + 1.67  male gender + 2.34  log (AFP) + 0.04 
 AFP-L3 + 1.33  log (DCP). [Please confirm or correct formula][OK,  Again, not 
convinced that giving the formula helps.  An illustrative figure might be more 
informative] 
 
The main difference between [individual biomarker use by Toyoda and colleagues 
and use of the GALAD model?] is that the former used predefined biomarker cutoff 
points for being positive or negative, whereas the GALAD model considers the 
individual biomarkers in their continuous format. Using a continuous format is probably 
better than using predefined cutoffs.; [Please explain why.]the latter "wastes" much 
information. 
 
G&H Why did you and your colleagues choose to use AFP, AFP-L3, and DCP when 
building HCC biomarker models? [rewording ok?] 
 
PJ Those biomarkers were chosen because they are available on a commercial 
platform, they are very well-characterized assays, and there is a vast amount of data on 
them from Japan for further analysis.  
 
G&H Based upon the data available thus far, how does the performance of the GALAD 
model compare with that of the individual biomarkers? [rewording ok?] 
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 PJ The best way of examining the performance of a model such as GALAD is to 
look at its area under the receiver operating characteristic curve. This number provides a 
general description of how good a model is. It is clear that AFP, AFP-L3, and DCP are 
each diagnostically distinctive. When these 3 biomarkers are combined, [diagnosis?] 
improves in all populations and stages of the disease. The GALAD model is clearly better 
than using the biomarkers separately. [Diagram to support this contention]. [Please 
provide some specific data from 1 or more studies.] 
 
G&H How sensitive and specific is the GALAD model? 
 
PJ It is important to keep in mind that sensitivity and specificity are reciprocally 
related, so if sensitivity is high, then specificity goes down, and vice-versa. Optimal 
sensitivity and specificity are in the order of approximately 0.85—ie, approximately 85% 
sensitive and approximately 85% specific. However, the sensitivity and specificity of the 
GALAD model vary across different subgroups and disease stages, which is why the area 
under the receiver operating characteristic curve is better to use. [Should we delete this 
question and answer?][OK as above] 
 
G&H Has the GALAD model been examined in terms of different underlying liver 
disease and race? 
 
PJ Yes. The model seems to be roughly as effective irrespective of disease etiology. 
[Please provide some specific data] Diagram 
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An abstract presented at last year’s European Association of the Study of the Liver 
meeting by Dr Ju Dong Yang, on behalf of colleagues at the Mayo Clinic including lead 
investigator Dr Lewis Roberts, examined the use of the GALAD model in various 
subgroups, including different races, in several large US centers. [edits to sentence ok?] 
[OK]Under the aegis of the National Cancer Institute Early Detection Research Network, 
the researchers concluded that the performance of the GALAD model for HCC diagnosis 
in a multicenter US cohort was excellent. They also found that the sensitivity, specificity 
and AUROC varied slightly according to ethnicity, aetiology and disease stage.the results 
slightly differed according to race (black vs white). [Please provide some specific data] 
 
G&H Has the GALAD model been used in early- and late-stage HCC? 
 
PJ Yes, the abstract by Yang and colleagues found that the GALAD model works 
well in both settings. [Please provide some specific data] and  
 
Iin a study published [by my colleagues and I?][OK], the GALAD model even worked 
well irrespective of tumor size, which was a surprise. [Please provide some specific 
data] [Figure]  
 
G&H Does the GALAD model have any other roles in HCC? 
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 PJ That is an area of active investigation at the moment. The GALAD score appears 
to be proportional to the tumor cell mass. Thus, in the future, the GALAD model might 
be useful for monitoring treatment. Even more controversially, the score appears to be 
elevated before cancer can be seen on a scan, which means that it may have a role in the 
surveillance setting for very early diagnosis of HCC. However, more research is needed 
on both of these issues. [edits throughout this paragraph ok?][OK as is] 
 
G&H What studies have been conducted using the BALAD-2 model? 
 
PJ A large, recent, international, multicenter study conducted by Dr Sarah Berhane 
and colleagues (of which I was a part) described the prognostic use of BALAD-2 in 
detail. WeThe authors concluded that BALAD-2 provides an extremely good indication 
of the prognosis of HCC patients irrespective of etiology and cancer size.  and in [Could 
you provide more detail/data?] 
 
In a recent nationwide study of Japan conducted by Toyoda and colleagues, BALAD-2 
showed a modest improvement (ie, better prognostic performance) over the original 
BALAD model across all stages of disease and all etiologies. [Could you provide more 
detail/data?] [Figures] 
 
G&H What are the advantages and disadvantages of the GALAD model? 
 
 PJ One advantage is that it is entirely objective; it does not require any subjective 
factors or interpretation of radiographic images. Another advantage is that it is easy to 
determine the score, which can be done with an online calculator (eg, at 
http://www.mayoclinic.org/medical-professionals/model-end-stage-liver-disease/galad) 
or a smartphone application.  
 
A disadvantage of both models is that, at the moment, there is a relatively small number 
of laboratories that will perform the 3 biomarker assays. Such laboratories are numerous 
in Japan and are starting to increase in Europe and the United States, but are not yet 
widespread. A second disadvantage, common to all serological approaches to early 
diagnosis, is that whilst the GALAD model may suggest that an HCC has developed it 
doesn't say "where" it is.  Only radiology can perform this task. 
 
[Do the above 2 advantages and 1 disadvantage also apply to BALAD-2? If so, can 
we change the question to “What are the advantages and disadvantages of the 2 
biomarker models?” and then still include the disadvantage of the BALAD-2 listed 
below?] 
 
G&H What are the advantages and disadvantages of the BALAD-2 model?  [Answered 
above] 
 
PJ The BALAD-2 model works well. If a patient’s AFP, AFP-L3, and DCP are 
available, it is possible to obtain a good idea of the patient’s outlook. 
  
However, I think that the BALAD-2 score is very much a secondary output from these 3 
biomarkers, with the GALAD score being more important. I think it is fair to say that a 
[medical center?] would not measure AFP, AFP-L3, and DCP [only to obtain?][OK] a 
BALAD-2 score. The reason that these biomarkers would be measured every day would 
be to obtain a GALAD score (ie, for diagnosis) and since the 3 biomarkers are measured, 
then that information could also be used for the BALAD-2 model for screening (ie, for 
prognosis). [edits to sentence ok?]  
 
G&H Do you think that these models will eventually replace the use of individual 
biomarkers and/or imaging? 
 
PJ It remains to be seen. [However, there may always be a need for radiologic 
imaging?]. For example, the GALAD score can indicate whether a patient has a cancer 
or is likely to develop one. What it cannot do is show where that cancer is located in the 
liver. [this sentence - a disadvantage of GALAD could come in here or as inserted 
above - up to you]For many forms of treatment, particularly early treatment, it is 
necessary to know exactly where the cancer is located. Most likely, if these models prove 
to be successful in prospective trials, they would be used in combination with current 
radiology. [edits ok?] 
 
G&H Are other biomarker models also being investigated in HCC? 
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 PJ There are currently numerous biomarker models being examined. However, in 
many cases, these are developed in individual laboratories, reportedthere is little research 
on these models in the literature, and then no further steps are taken because the assays 
are not robust enough to be transferred consistently around the world. [edits to sentence 
ok?][OK] 
 
G&H What are the next steps in research regarding the GALAD and BALAD-2 
models? 
 
PJ The most important next step is further prospective study, and there are at least 2 
prospective studies currently being conducted. One is being performed in Toronto, 
Canada with Dr Morris Sherman as the lead investigator. The other study, which is being 
led by Dr Hashem El-Serag in Texas, will be reporting its findings in the next few weeks. 
These studies will help determine whether the GALADis model [which model?] 
becomes more widely applied. 
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